MTN-017: A rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel

• Main Authors: Cranston R., Lama J., Richardson B., Carballo-Diéguez A., Na Ayudhya R., Liu K., Patterson K., Leu C., Galaska B., Jacobson C., Parikh U., Marzinke M., Hendrix C., Johnson S., Piper J., Grossman C., Ho K., Lucas J., Pickett J., Bekker L., Chariyalertsak S., Chitwarakorn A., Gonzales P., Holtz T., Liu A., Mayer K., Zorrilla C., Schwartz J., Rooney J., McGowan I.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85018192380&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/41179
• Institution: Chiang Mai University

© The Author 2017. Background. Human immunodeficiency virus (HIV) disproportionately affects men who have sex with men (MSM) and transgender women (TGW). Safe and acceptable topical HIV prevention methods that target the rectum are needed. Methods. MTN-017 was a phase 2, 3-period, randomized sequenc...